Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRIDGE Trial: Phase II Trial of durvalumaB and chemotheRapy Induction Followed by Durvalumab and Radiotherapy in larGe volumE Stage III NSCLC

NCT04765709 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT04765709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04765709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRIDGE Trial: Phase II Trial of durvalumaB and chemotheRapy Induction Followed by Durvalumab and Radiotherapy in larGe volumE Stage III NSCLC
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 2
Overall status
Terminated
Start date
September 24, 2021
Completion date
January 30, 2025
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer stage iii